APRACLONIDINE HYDROCHLORIDE - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for apraclonidine hydrochloride and what is the scope of patent protection?

Apraclonidine hydrochloride is the generic ingredient in two branded drugs marketed by Rising and Harrow Eye, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for apraclonidine hydrochloride. Two suppliers are listed for this compound.

Summary for APRACLONIDINE HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	3
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	3
Patent Applications:	606
What excipients (inactive ingredients) are in APRACLONIDINE HYDROCHLORIDE?	APRACLONIDINE HYDROCHLORIDE excipients list
DailyMed Link:	APRACLONIDINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for APRACLONIDINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Alabama at Birmingham	Phase 4
American University of Beirut Medical Center	Phase 2
Walter Reed Army Medical Center	N/A

See all APRACLONIDINE HYDROCHLORIDE clinical trials

Pharmacology for APRACLONIDINE HYDROCHLORIDE

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

Anatomical Therapeutic Chemical (ATC) Classes for APRACLONIDINE HYDROCHLORIDE

US Patents and Regulatory Information for APRACLONIDINE HYDROCHLORIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	APRACLONIDINE HYDROCHLORIDE	apraclonidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	077764-001	Mar 12, 2009	AT	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Harrow Eye	IOPIDINE	apraclonidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019779-001	Dec 31, 1987		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Harrow Eye	IOPIDINE	apraclonidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020258-001	Jul 30, 1993	AT	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for APRACLONIDINE HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	IOPIDINE	apraclonidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020258-001	Jul 30, 1993	⤷ Sign Up	⤷ Sign Up
Harrow Eye	IOPIDINE	apraclonidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019779-001	Dec 31, 1987	⤷ Sign Up	⤷ Sign Up
Harrow Eye	IOPIDINE	apraclonidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019779-001	Dec 31, 1987	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.